𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II clinical trial of the combination VP-16, bleomycin, and cis-diamminedichloroplatinum in patients with advanced upper aerodigestive squamous cell carcinoma

✍ Scribed by Creagan, Edward T. ;Chang, Myron ;Long, Harry J. ;Rubin, Joseph

Publisher
Wiley (John Wiley & Sons)
Year
1987
Weight
348 KB
Volume
9
Category
Article
ISSN
0148-6403

No coin nor oath required. For personal study only.

✦ Synopsis

Fifteen patients with advanced upper aerodigestive carcinomas of squamous cell histology received the three-agent cytotoxic regimen of VP-16, bleornycin, and cis-diamminedichloroplatinum (CDDP) administered as a continuous 120-h infusion. The objective response rate was 40%. Median times to progression and survival were 3.2 months and 4.3 months, respectively. Hematologic and gastrointestinal toxicities were relatively transient and manageable. Our experience indicates that this three-drug program does not offer a substantial therapeutic advantage compared with more conventional single agent cytotoxic approaches for advanced head and neck cancer. HEAD & NECK SURGERY 9:223-226,1987

Single agent chemotherapy in advanced head and neck cancer using platinum (P) achieves objective regressions in 30-40% of patients in an array of doses and s~hedules.l-~ Unfortunately, there is no evidence that P has enhanced the survival of these patients. A 120-h infusion of P is clinically tol-From the Division of Medical Oncology, Mayo Clinic and Mayo Foundation.

πŸ“œ SIMILAR VOLUMES

A phase II clinical trial of the combina
A phase II clinical trial of the combination mitomycin C, adriamycin, andcis-diamminedichloroplatinum in patients with advanced upper aerodigestive cancer
✍ Creagan, Edward T. ;Chang, Myron ;Long, Harry J. ;Rubin, Joseph πŸ“‚ Article πŸ“… 1986 πŸ› Wiley (John Wiley & Sons) βš– 517 KB

Twenty-seven patients with assessable, regionally advanced, or metastatic upper aerodigestive cancer of diverse histology received a combination of mitomycin C, adriamycin, and cisdiamminedichloroplatinum. All patients had previously received extensive surgery and/or radiation therapy. We observed a

UFT plus cisplatin combination chemother
UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma : A multiinstitutional Phase II trial
✍ Yukito Ichinose; Kozo Yosimori; Shuichi Yoneda; Mutsuo Kuba; Shoji Kudoh; Hisano πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 77 KB πŸ‘ 2 views

## Background: Combination chemotherapy comprised of oral uft (a combination of tegafur and uracil) and cisplatin was shown to be an effective regimen for the treatment of advanced nonsmall cell lung carcinoma and to be associated with a low incidence rate of toxicity in a previous, single institut

Phase II clinical trial of parenteral hy
Phase II clinical trial of parenteral hydroxyurea and hyperfractionated, accelerated external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck: Toxicity and efficacy with continuous ribonucleoside reductase inhibition
✍ Jonathan J. Beitler; Richard V. Smith; Randall P. Owen; Carl E. Silver; Madhu Ma πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 398 KB πŸ‘ 2 views

## Abstract ## Background Almost all concurrent chemoradiation regimens for head and neck are platinum based; however, cisplatin is associated with severe renal, oto‐, and neurotoxicity. Hydroxyurea (HU) has been associated with fewer irreversible toxicities. We obtained HU in parenteral form to b

A phase II trial of cisplatin, methotrex
A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck
✍ Francesco Caponigro; Pasquale Comella; Paolo Marcolin; Francesco Russo Spena; Ma πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 89 KB πŸ‘ 2 views

## Background: Induction chemotherapy in locoregionally advanced squamous cell carcinoma of the head and neck (scchn) might improve survival with respect to radiation therapy alone. furthermore, chemotherapy represents the only therapeutic option in metastatic head and neck carcinoma. ## Methods: